Direct Relief, BD, NAFC Announce Free and Charitable Clinic Grant Winners
January 26, 2022 10:28 ET
|
National Association of Free & Charitable Clinics
Alexandria, VA, Jan. 26, 2022 (GLOBE NEWSWIRE) -- In their continued effort to help vulnerable populations access health care services that address chronic disease, Direct Relief, BD (Becton,...
Casana Closes $30 Million Series B Funding to Accelerate Development of Novel Effortless Home Health Monitoring
January 21, 2022 12:15 ET
|
Casana Care, Inc.
ROCHESTER, N.Y., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Casana, a healthcare technology firm that is reinventing in-home health monitoring, announced today that it has raised $30 million in Series B...
Cardiometabolic Diseases Market Size ($121,804.49Mn by 2028) Lead by Cardiovascular Disease (3.9% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 29, 2021 09:54 ET
|
The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cardiometabolic Diseases Market: Key InsightsAccording to our new research study on Cardiometabolic Diseases Market Size and Forecast to 2028 - COVID-19...
Embolization Agents Market Size ($4,525.75Mn by 2028) Lead by Coil Segment (7.6% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 22, 2021 08:22 ET
|
The Insight Partners
New York, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The new research study on the Embolization Agents Market Size and Forecast to 2028 by Product (Coils, Plugs, Beads/Particles, Detachable Balloons, Glue,...
Worldwide Diltiazem Industry to 2028 - Increase in Cardiovascular Disease Incidence is Driving Growth
October 21, 2021 06:58 ET
|
Research and Markets
Dublin, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The "Global Diltiazem Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Capsules, Injection, and Tablets); Application (Angina,...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment
September 16, 2021 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud...
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System
September 15, 2021 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation
August 06, 2021 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment
August 04, 2021 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension
June 16, 2021 08:00 ET
|
KBP BioSciences
KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic systolic blood pressure (SBP) by 10.2 mm Hg with reduced hyperkalemia risk in the phase 2b studyArticle...